Bruker AXS Announces Technology Joint Venture for Innovative X-ray Optics.Business Editors MADISON, Wis adv. 1. Certainly; really; indeed. v. t. 1. To think; to suppose; to imagine; - used chiefly in the first person sing. present tense, I wis. See the Note under Ywis. .--(BUSINESS WIRE)--Feb. 1, 2002 Bruker AXS Bruker AXS is an international instrument manufacturer and supplier. The company is part of Bruker and specialized on Analytical X-Ray Systems. The main parts are the X-Ray diffraction and the X-Ray spectrometry. Inc. (Nasdaq: BAXS), a leading global provider of advanced X-ray solutions for the life and advanced materials Advanced Materials is a leading peer-reviewed materials science journal published every two weeks. Advanced Materials includes Communications, Reviews, and Feature Articles from the cutting edge of materials science, including topics in chemistry, physics, sciences, announced today that it has entered into a joint venture for research, development and production of X-ray optics X-ray optics By analogy with the science of optics, those aspects of x-ray physics in which x-rays exhibit properties similar to those of light waves. based on innovative coating technologies. As part of the joint venture, Bruker AXS will hold a 51% stake in INCOATEC GmbH, a German company that was spun-off from the GKSS GKSS Gesellschaft zur Förderung der Kernenergie in Schiffbau und Schiffstechnik (German: society for the promotion of the nuclear energy in shipbuilding and naval technology) , a materials research center located in Geesthacht, Germany. Dr. Martin Haase, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Bruker AXS, said, "This joint venture further enhances our already broad in-house technology portfolio, and allows us to drive development of next-generation optics technologies for our life science and materials science materials science Study of the properties of solid materials and how those properties are determined by the material's composition and structure, both macroscopic and microscopic. systems. GKSS will license its relevant patents to INCOATEC, which will be managed by Dr. Carsten Michaelsen and Dr. Joerge Wiesmann, two leading scientists in the field of coating technologies." He continued, "We have been working with the GKSS scientists for several years, and we are very pleased to see our long-standing R&D collaboration now result in the commercialization of high-intensity X-ray optics which will improve the performance of our products even further. Bruker AXS will exclusively market the INCOATEC products through its established global distribution organization, and will provide capital and R&D resources to optimize the use of these optics in the field of X-ray instrumentation." Dr. Carsten Michaelsen, Co-Managing Director of INCOATEC GmbH, added, "We are excited about the formation of this joint venture with Bruker AXS. It will allow us to deploy the technologies which we have developed in the last decade. Bruker AXS' excellent R&D and distribution organization will not only enable us to grow our business but will also bring opportunities for further development." "The formation of technology ventures is fully in line with GKSS' strategy, and we strongly support this venture. We are proud to see our technologies being commercialized through a technology company founded by our scientists. The financial and R&D involvement of Bruker AXS will guarantee the long-term future of this new company. This is the way we like R&D collaborations to evolve," commented Dr. Guenter von Sengbusch, Scientific Director of the GKKS research center. About Bruker AXS Bruker AXS is a leading worldwide developer and provider of advanced X-ray systems which provide solutions for molecular and elemental analysis Elemental analysis is a process where a sample of some material (e.g., soil, waste or drinking water, bodily fluids, minerals, chemical compounds) is analyzed for its elemental and sometimes isotopic composition. by X-ray crystallography X-ray crystallography, the study of crystal structures through X-ray diffraction techniques. When an X-ray beam bombards a crystalline lattice in a given orientation, the beam is scattered in a definite manner characterized by the atomic structure of the lattice. , X-ray diffraction and X-ray fluorescence X-ray fluorescence (XRF) is the emission of characteristic "secondary" (or fluorescent) X-rays from a material that has been excited by bombarding with high-energy X-rays or gamma rays. . Its integrated systems, which have particular application in the drug discovery and materials science fields, provide customers with high throughout capabilities to determine the structure of specific molecules, such as proteins, and to characterize and determine the composition of materials. Bruker AXS' substantial investment in research and development allows it to design, manufacture and market technologically innovative, integrated solutions to meet the rapidly growing needs of a diverse customer base, including biotechnology and pharmaceutical companies, semiconductor companies, raw materials manufacturers, chemical companies, academic institutions and other businesses involved in materials analysis. Bruker AXS Safe-Harbor Statement Statements in this press release that are not strictly historical are "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements involve a high degree of risk and uncertainty that exist in the Company's operations and business environment. Such statements are predictions only and actual events or results may differ materially from those projected in such forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. . Factors that could affect actual events or results include risks associated with performance under the Company's agreements with third parties, research and development progress, competitive products and the strength of the Company's patent portfolio. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion